Medicine
fromNews Center
1 day agoCAR T-cell Therapy Improves Survival in Relapsed or Refractory Lymphoma - News Center
CAR T-cell therapy lisocabtagene maraleucel significantly improved progression-free and overall survival in patients with relapsed or refractory marginal zone lymphoma.